Pharsight

Drugs that contain Metformin Hydrochloride; Pioglitazone Hydrochloride

1. Actoplus Met patents expiration

ACTOPLUS MET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5965584 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US6166042 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US6166043 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US6172090 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US9101660 TAKEDA PHARMS USA Solid preparation
Jan, 2027

(2 years from now)

US9320714 TAKEDA PHARMS USA Tablet
Feb, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-116) May 17, 2015

Market Authorisation Date: 29 August, 2005

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione (tzd) and metformin or who have inadequate glycemic...

Dosage: TABLET;ORAL

More Information on Dosage

ACTOPLUS MET family patents

Family Patents

2. Actoplus Met Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6172090 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US6166043 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US5965584 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US6166042 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(7 years ago)

US7919116 TAKEDA PHARMS USA Controlled release metformin formulations
Mar, 2018

(6 years ago)

US6495162 TAKEDA PHARMS USA Controlled release oral tablet having a unitary core
Mar, 2018

(6 years ago)

US8475841 TAKEDA PHARMS USA Controlled release metformin formulations
Mar, 2018

(6 years ago)

US6099859 TAKEDA PHARMS USA Controlled release oral tablet having a unitary core
Mar, 2018

(6 years ago)

US6790459 TAKEDA PHARMS USA Methods for treating diabetes via administration of controlled release metformin
Mar, 2021

(3 years ago)

US6866866 TAKEDA PHARMS USA Controlled release metformin compositions
Mar, 2021

(3 years ago)

US8668931 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(8 months ago)

US8470368 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(8 months ago)

US9060941 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Sep, 2023

(8 months ago)

US7785627 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Jul, 2026

(2 years from now)

US7959946 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Jul, 2026

(2 years from now)

Market Authorisation Date: 12 May, 2009

Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with pioglitazone and metformin or who have inadequate glycemic control on piog...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ACTOPLUS MET XR before it's drug patent expiration?
More Information on Dosage

ACTOPLUS MET XR family patents

Family Patents